Cargando…
An audit assessing the monitoring of SSRIS after initiation in children and adolescents
AIMS: To identify children and adolescents started on SSRIs to see if they are being followed up in accordance to NICE and Maudsley guidelines Objectives Has the patient been followed up after a week to check for adverse effects or improvement in their mental state? Has the patient been re-evaluated...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771488/ http://dx.doi.org/10.1192/bjo.2021.159 |
_version_ | 1784635613616537600 |
---|---|
author | McGowan, Ella |
author_facet | McGowan, Ella |
author_sort | McGowan, Ella |
collection | PubMed |
description | AIMS: To identify children and adolescents started on SSRIs to see if they are being followed up in accordance to NICE and Maudsley guidelines Objectives Has the patient been followed up after a week to check for adverse effects or improvement in their mental state? Has the patient been re-evaluated every 4-6 weeks, if not is there an alternative plan? If there is no improvement has the dose been increased? If there is an adverse effect has the dose been lowered or the medication stopped? METHOD: Paper case notes including clinic letters and handwritten notes were reviewed on the 19/10/2020. The following data were collected anonymously. Age Gender Date seen / Date medication started Name of medication Date medication started Date of Follow-up Monitoring of improvement Monitoring of adverse effects Outcome of monitoring RESULT: A total of 18 sets of cases were identified. Follow-up occurred in 17 of the 18 cases. The one case that had not been followed up had started the medication 8 weeks before the audit. The median follow-up time was 42 days (6 weeks). No cases were followed up within a week. Monitoring of improvement was recorded in 88% of case notes reviewed. Monitoring for adverse effects occurred in 36% of case notes and none of these patients had reported any side effects. 53% of cases did not have monitoring of adverse effects documented. There were two patients (11%) who did not take the medication as prescribed. One out of choice and one their parent had not collected it. The medication dose was increased in 22% of patients without clear documentation of monitoring for adverse effects. CONCLUSION: After discussion with the clinical lead it was decided it is impractical to follow up patients a week after starting medication. However, patients and their carers should be informed of the side effects and advised to contact CAMHS if adverse effects occur. The area of practice that can be improved is the documentation of adverse effects at follow-up. Recommendations: All patients to be informed of the common side effects of the medication before it is initiated and advised to contact the CAMHS team if they have concerns All CAMHS patients started on SSRIs should be followed up within 4-6 weeks At follow-up any adverse events and clinical response should be discussed An accurate record of the exchanges of the above information should be documented in the notes Re-audit |
format | Online Article Text |
id | pubmed-8771488 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-87714882022-01-31 An audit assessing the monitoring of SSRIS after initiation in children and adolescents McGowan, Ella BJPsych Open Rapid-Fire Poster Presentations AIMS: To identify children and adolescents started on SSRIs to see if they are being followed up in accordance to NICE and Maudsley guidelines Objectives Has the patient been followed up after a week to check for adverse effects or improvement in their mental state? Has the patient been re-evaluated every 4-6 weeks, if not is there an alternative plan? If there is no improvement has the dose been increased? If there is an adverse effect has the dose been lowered or the medication stopped? METHOD: Paper case notes including clinic letters and handwritten notes were reviewed on the 19/10/2020. The following data were collected anonymously. Age Gender Date seen / Date medication started Name of medication Date medication started Date of Follow-up Monitoring of improvement Monitoring of adverse effects Outcome of monitoring RESULT: A total of 18 sets of cases were identified. Follow-up occurred in 17 of the 18 cases. The one case that had not been followed up had started the medication 8 weeks before the audit. The median follow-up time was 42 days (6 weeks). No cases were followed up within a week. Monitoring of improvement was recorded in 88% of case notes reviewed. Monitoring for adverse effects occurred in 36% of case notes and none of these patients had reported any side effects. 53% of cases did not have monitoring of adverse effects documented. There were two patients (11%) who did not take the medication as prescribed. One out of choice and one their parent had not collected it. The medication dose was increased in 22% of patients without clear documentation of monitoring for adverse effects. CONCLUSION: After discussion with the clinical lead it was decided it is impractical to follow up patients a week after starting medication. However, patients and their carers should be informed of the side effects and advised to contact CAMHS if adverse effects occur. The area of practice that can be improved is the documentation of adverse effects at follow-up. Recommendations: All patients to be informed of the common side effects of the medication before it is initiated and advised to contact the CAMHS team if they have concerns All CAMHS patients started on SSRIs should be followed up within 4-6 weeks At follow-up any adverse events and clinical response should be discussed An accurate record of the exchanges of the above information should be documented in the notes Re-audit Cambridge University Press 2021-06-18 /pmc/articles/PMC8771488/ http://dx.doi.org/10.1192/bjo.2021.159 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Rapid-Fire Poster Presentations McGowan, Ella An audit assessing the monitoring of SSRIS after initiation in children and adolescents |
title | An audit assessing the monitoring of SSRIS after initiation in children and adolescents |
title_full | An audit assessing the monitoring of SSRIS after initiation in children and adolescents |
title_fullStr | An audit assessing the monitoring of SSRIS after initiation in children and adolescents |
title_full_unstemmed | An audit assessing the monitoring of SSRIS after initiation in children and adolescents |
title_short | An audit assessing the monitoring of SSRIS after initiation in children and adolescents |
title_sort | audit assessing the monitoring of ssris after initiation in children and adolescents |
topic | Rapid-Fire Poster Presentations |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8771488/ http://dx.doi.org/10.1192/bjo.2021.159 |
work_keys_str_mv | AT mcgowanella anauditassessingthemonitoringofssrisafterinitiationinchildrenandadolescents AT mcgowanella auditassessingthemonitoringofssrisafterinitiationinchildrenandadolescents |